AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
ER-Positive HER2-Negative Breast Cancer
Conditions
ER-Positive HER2-Negative Breast Cancer
Trial Timeline
Jan 28, 2021 → Feb 1, 2029
NCT ID
NCT04711252About AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist
AZD9833 + Anastrozole + Anastrozole placebo + AZD9833 placebo + Palbociclib + Luteinizing hormone-releasing hormone (LHRH) agonist is a phase 3 stage product being developed by AstraZeneca for ER-Positive HER2-Negative Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04711252. Target conditions include ER-Positive HER2-Negative Breast Cancer.
What happened to similar drugs?
0 of 1 similar drugs in ER-Positive HER2-Negative Breast Cancer were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04711252 | Phase 3 | Active |
Competing Products
6 competing products in ER-Positive HER2-Negative Breast Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Fulvestrant Run-In | Eli Lilly | Phase 2 | 42 |
| AZD9833 + AZD9833 Placebo + Anastrozole + Anastrozole placebo + Letrozole + Letrozole placebo + Palbociclib + Abemaciclib + Luteinizing hormone-releasing hormone (LHRH) agonist + Ribociclib | AstraZeneca | Phase 3 | 44 |
| [14C]AZD9833 Oral Solution, 75 mg | AstraZeneca | Phase 1 | 29 |
| AZD9833 + Fulvestrant | AstraZeneca | Phase 2 | 39 |
| Giredestrant + Abemaciclib + Ipatasertib + Inavolisib + Ribociclib + Everolimus + Samuraciclib + PH FDC SC + Palbociclib + Atezolizumab | Roche | Phase 1/2 | 39 |
| Onapristone + Fulvestrant | Context Therapeutics | Phase 2 | 17 |